HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

GpG-oligonucleotide

immunomodulatory GpG oligonucleotide contains a single base switch from cytosine to guanine

Also Known As:

GpG-ODN

Networked: 3 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Nucleic Acids, Nucleotides, and Nucleosides: 1
- Nucleotides: 15763
  - Polynucleotides: 218
    - Oligonucleotides: 5145
      - Oligodeoxyribonucleotides: 2217
        GpG-oligonucleotide: 3

Experts

1.	Ho, Peggy P: 3 articles (03/2010 - 11/2003)
2.	Steinman, Lawrence: 3 articles (03/2010 - 11/2003)
3.	Lee, Lowen Y: 2 articles (03/2010 - 11/2005)
4.	Fontoura, Paulo: 2 articles (11/2005 - 11/2003)
5.	Garren, Hideki: 2 articles (11/2005 - 11/2003)
6.	Graham, Kareem L: 1 article (03/2010)
7.	Higgins, John P: 1 article (03/2010)
8.	Utz, Paul J: 1 article (03/2010)
9.	Agrawal, Ashish: 1 article (11/2005)
10.	Capers, Julien: 1 article (11/2005)

Related Diseases

1.	Autoimmune Diseases (Autoimmune Disease) 11/01/2005 - "These results demonstrate that suppressive GpG-ODN is a simple and highly effective novel therapeutic adjuvant that will boost the efficacy of Ag-specific tolerizing DNA vaccines used for treating Th1-mediated autoimmune diseases." 11/01/2003 - "In this study, we show that the application of an immunomodulatory GpG ODN, with a single base switch from CpG to GpG, can effectively inhibit the activation of Th1 T cells associated with autoimmune disease. " 11/01/2005 - "In conclusion, suppressive GpG-ODN effectively counteracted the undesired CpG-induced inflammatory effect of a tolerizing DNA vaccine in a Th1-mediated autoimmune disease by skewing both the autoaggressive T cell and B cell responses toward a protective Th2 phenotype. "
2.	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 11/01/2003 - "Moreover, this immunomodulatory GpG ODN suppresses the severity of experimental autoimmune encephalomyelitis in mice, a prototypic Th1-mediated animal disease model for multiple sclerosis." 11/01/2005 - "In chronic relapsing experimental autoimmune encephalomyelitis (EAE), combining a myelin cocktail plus IL-4-tolerizing DNA vaccine with a suppressive GpG oligodeoxynucleotide (GpG-ODN) induced a shift of the autoreactive T cell response toward a protective Th2 cytokine pattern. "
3.	Proteinuria 03/01/2010 - "While CpG-ODN treatment did not appear to have a major impact on disease severity, GpG-ODN treatment significantly delayed the onset of proteinuria in NZB/W mice. "
4.	Multiple Sclerosis 11/01/2003 - "Moreover, this immunomodulatory GpG ODN suppresses the severity of experimental autoimmune encephalomyelitis in mice, a prototypic Th1-mediated animal disease model for multiple sclerosis."
5.	Lupus Nephritis 03/01/2010 - "Taken together, the data indicate that the protective mechanism of GpG-ODN treatment in the NZB/W model of lupus nephritis involves modulating T cell cytokine profiles and B lymphocyte activation through the inhibition of several TLRs, including TLR-7 and TLR-9." 03/01/2010 - "Treatment with a toll-like receptor inhibitory GpG oligonucleotide delays and attenuates lupus nephritis in NZB/W mice."

Related Drugs and Biologics

1.	DNA Vaccines
2.	guanylyl-(3'-5')-guanosine
3.	Cytokines
4.	Toll-Like Receptors (Toll-Like Receptor)
5.	Oligodeoxyribonucleotides
6.	CPG-oligonucleotide